Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 600,000 | 16.4% |
| Gross Profit | -17M | 11.3% |
| Cost of Revenue | 17M | 10.6% |
| Operating expense | 111M | 27% |
| Net Income | -86M | 32% |
| EBITDA | -110M | 24.8% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 2.26B | 3.6% |
| Total Liabilities | 316M | 11.8% |
| Total Equity | 1.94B | 2.1% |
| Shares Outstanding | 85M | 0.3% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -107M | 11.9% |
| Cash from investing | -162M | 27.3% |
| Cash from financing | 9.6M | 2168.7% |
EPS
Financial Highlights for Crispr Therapeutics in Q3 '24
Crispr Therapeutics reported a revenue of 600,000, which is a 16.4% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -17M, marking a 11.3% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 17M, a -10.6% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 111M, showing a -27% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -86M, showing a 32% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -110M, showing a 24.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Crispr Therapeutics with growth in revenue, gross profit, and net income.
